Milestone Scientific INC. Stock: price and directors' dealings · United States · SEC (Form 4)

About Milestone Scientific INC.

Milestone Scientific Inc. is a U.S.-based medical technology company listed on NYSE American, part of the NYSE market, under the ticker MLSS. Incorporated in Delaware in August 1989, the company is headquartered in Roseland, New Jersey, United States. Its business is centered on computer-controlled injection and anesthetic delivery technologies designed to improve precision, pressure control, and patient comfort in both medical and dental procedures. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm)) The company’s core platform is its proprietary Dynamic Pressure Sensing (DPS) technology. Milestone has built its product portfolio around devices that aim to deliver injectable anesthetics and other liquids more accurately than conventional manual syringes. In dentistry, its brands include The Wand®, CompuDent®, and the STA Single Tooth Anesthesia System®. In medicine, the flagship platform is CompuFlo®, including the CompuFlo Epidural Computer Controlled Anesthesia System, which the company says can provide real-time visual and audible pressure feedback to help clinicians identify the epidural space with greater objectivity. The company received FDA clearance in June 2017 to market the CompuFlo Epidural System in the United States for epidural injections. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm)) Milestone occupies a specialized niche in the broader medical devices market rather than competing as a diversified device manufacturer. Its competitive edge is built on patent protection, a differentiated clinical workflow, and claims around improved accuracy, safety, and patient experience. At the same time, the business faces a demanding regulatory environment, strong competition from larger device makers, and execution risk tied to commercialization, reimbursement, and manufacturing partnerships. The company notes that it sells dental products through a mix of exclusive and non-exclusive distributors worldwide, while medical products are sold internationally through exclusive distributors in markets such as Italy, Switzerland, Greece, Canada, and the Middle East. In the United States, medical products are marketed through a small direct sales team and a distributor partnership. ([sec.gov](https://www.sec.gov/Archives/edgar/data/855683/000143774925012050/mlss20241231_10k.htm)) Recent developments indicate a company in transition. In its March 31, 2026 business update and full-year 2025 results, management said the business had moved from restructuring toward growth, highlighting tighter spending control, a relaunch of CompuFlo commercialization efforts, and the launch of a dental ambassador program pilot. Management also signaled expectations for stronger 2026 revenue momentum and continued progress toward profitability. For equity investors, MLSS remains a micro-cap healthcare story with potentially meaningful upside if adoption improves, but it also carries elevated risk tied to product uptake, reimbursement, and capital discipline. ([nasdaq.com](https://www.nasdaq.com/press-release/milestone-scientific-reports-financial-results-fourth-quarter-and-full-year-2025-2026))